Effects of Rebamipide for Dry Eye on Optical Quality and Efficacy: A Systematic Review and Meta-Analysis
Journal of Ocular Pharmacology and Therapeutics · 01.12.2024 · 40 (10) · 629-637
DOI: 10.1089/jop.2024.0098 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, online erschienen am 02.12.2024. Verfasst von Yu-Ling Yan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Hainan Hospital of Chinese PLA General Hospital, Sanya, China. Hauptthemen laut MEDLINE: Dry Eye Syndromes, Ophthalmic Solutions, Quinolones. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
Purpose
To evaluate the effects of rebamipide ophthalmic suspension on optical quality and efficacy of patients with dry eye under different conditions.
Methods
A comprehensive search across five databases (PubMed, Cochrane Library, Web of Science, China National Knowledge Infrastructure, and Wan Fang) was conducted for studies published through May 13, 2024, focusing on rebamipide for dry eye treatment.
Results
A total of 11 studies including 334 patients with dry eye were included. Tear breakup time (TBUT) values of patients with dry eye increased significantly after 2 weeks (standardized mean difference [SMD] =1.07, 95% confidence interval [CI] = [0.05, 2.09]), 4 weeks (SMD = 1.26, 95% CI = [0.77, 1.75]), and 12 weeks (SMD = 1.04, 95% CI = [0.37, 1.71]) of rebamipide treatment. Subgroup analysis revealed that patients with dry eye wearing soft contact lens (SCL) exhibited higher TBUT values after 4 weeks of rebamipide treatment compared with those who received rebamipide alone. In addition, rebamipide significantly improved fluorescein staining score of patients with dry eye after 4 weeks of treatment (SMD = −0.34, 95% CI = [−0.63, −0.06]). However, 4 weeks of rebamipide treatment showed no significant effect on Schirmer I test values (SMD = −0.04, 95%, CI = [−0.43, 0.35]) and higher-order aberrations (SMD = −0.73, 95% CI = [−1.77, 0.30]).
Conclusions
These results indicate a significant improvement in the efficacy of rebamipide treatment for patients with dry eye, particularly for those wearing SCL. The effect of rebamipide on visual quality was found to correlate with the underlying dry eye status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Hainan Hospital of Chinese PLA General Hospital, Sanya, China.
- School of Medicine, Nanjing University, Nanjing, China.
- Department of Ophthalmology, Jinling Hospital, Nanjing, China.
- School of Medicine, Southeast University, Nanjing, China.
- Department of Ophthalmology, Nanjing Drum Tower Hospital, Nanjing, China.
ORCID-Profile: Yu-Ling Yan
Zitieren
APA
Yan, Y. L., Chang, J. Y., Ling, X. R., & Xue, C. Y. (2024). Effects of Rebamipide for Dry Eye on Optical Quality and Efficacy: A Systematic Review and Meta-Analysis. Journal of Ocular Pharmacology and Therapeutics, 40(10), 629-637. https://doi.org/10.1089/jop.2024.0098
Vancouver
Yan YL, Chang JY, Ling XR, Xue CY. Effects of Rebamipide for Dry Eye on Optical Quality and Efficacy: A Systematic Review and Meta-Analysis. Journal of Ocular Pharmacology and Therapeutics. 2024;40(10):629-637. doi:10.1089/jop.2024.0098
BibTeX
@article{Yan2024,
author = {Yan, Yu-Ling and Chang, Jing-Yao and Ling, Xin-Ru and Xue, Chun-Yan},
title = {Effects of Rebamipide for Dry Eye on Optical Quality and Efficacy: A Systematic Review and Meta-Analysis},
journal = {Journal of Ocular Pharmacology and Therapeutics},
year = {2024},
volume = {40},
number = {10},
pages = {629--637},
doi = {10.1089/jop.2024.0098}
}
EUVIMED